Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 3/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16990686 | 0.92 | NAMPT (0.55) | HTTNAMPTTRPV1MAPK14ALDH1A1 | |
| SCHEMBL15573134 | 0.86 | HTT (0.80) | HTTNAMPTTRPV1MAPK14ALDH1A1 | |
| SCHEMBL16990657 | 0.84 | HTT (0.60) | HTTNAMPTTRPV1MAPK14ALDH1A1 | |
| SCHEMBL15574698 | 0.84 | HTT (0.62) | HTTNAMPTMAPK14ALDH1A1CYP3A4 | |
| SCHEMBL15574745 | 0.84 | RAF1 (0.59) | NAMPTTRPV1ALDH1A1BRAFDDR2 | |
| SCHEMBL15574842 | 0.83 | NAMPT (0.79) | HTTNAMPTMAPK14BRAFKDR | |
| SCHEMBL15575399 | 0.83 | HTT (0.60) | HTTNAMPTTRPV1MAPK14ALDH1A1 | |
| SCHEMBL16990586 | 0.81 | NAMPT (0.64) | HTTNAMPTTRPV1MAPK14BRAF | |
| SCHEMBL15574561 | 0.81 | NAMPT (0.61) | HTTNAMPTMAPK14ALDH1A1CYP3A4 | |
| SCHEMBL15574787 | 0.81 | KDR (0.76) | NAMPTMAPK14BRAFKDRTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | claimed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | HTT 3579/4885NAMPT 2021/4885TRPV1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.